While the improvement in outcomes for children with acute lymphoblastic leukemia (ALL) has been gratifying, the poor outcome of patients who relapse warrants novel treatment approaches.
Introduction
Relapsed ALL is one of the leading causes of death among children with cancer. A hallmark of relapsed blasts is their intrinsic chemoresistance compared to what is observed at initial diagnosis. 1, 2 Given the frequent failure of conventional salvage chemotherapy including intensified drug schedules and stem cell transplantation in the treatment of relapsed ALL, 3, 4 innovative strategies are urgently needed.
In recent years it has become clear that cancer can be driven by patterns of altered gene expression mediated by mechanisms that do not affect the primary DNA sequence, but through the "epigenetic" processes of DNA promoter methylation and histone modification. 5, 6 DNA methylation is catalyzed by DNA methyltransferases (DNMTs) and has been shown to be an important contributor to carcinogenesis by silencing tumor suppressor genes in many tumor types, including hematologic malignancies. 6, 7 Chromatin structure is also regulated by the "histone code", which refers to post-translational modifications (methylation, acetylation, phosphorylation, ubiquitination) of key lysine residues on core histone proteins. 8 These two epigenetic processes of DNA promoter methylation and histone modifications are clearly interdependent and coordinated. [9] [10] [11] [12] DNMTi such as 5-azacitidine and decitabine have the potential to reverse promoter hypermethylation in tumor cells, leading to re-expression of aberrantly silenced genes, and induce tumor cell death. 13 DNMTi's have been demonstrated to be effective therapy for myelodysplastic syndrome (MDS), which is characterized by global promoter hypermethylation. 14 Likewise, inhibition of histone deacetylases with HDACi's such as vorinostat can alter the balance in favor of histone acetyltransferases (HATs), resulting in an increased acetylation of histone H3K9 and H3K14 and gene transcription. 15 Recently, we performed an integrated analysis to identify biological pathways underlying relapsed ALL using genome wide gene expression arrays, SNP arrays and DNA methylation arrays. 16 We have identified a relapse specific gene expression signature characterized by upregulation of genes involved in regulation of cell cycle and apoptosis (BIRC5, FOXM1,
For personal use only. on August 16, 2017. by guest www.bloodjournal.org From GTSE1), DNA replication and repair (FANCD2) and nucleotide biosynthesis (TYMS, CAD, PAICS, ATIC, DHFR); and by downregulation of genes involved in sensitivity to thiopurines and alkylators (MSH6) and glucocorticoids (BTG1 and NR3C1). In addition, our genome wide methylation analysis revealed a distinctly higher CpG methylation level in the relapsed cohort compared to diagnosis, 16 and for a subset of differentially methylated genes, concordant downregulation of mRNA expression was observed, implicating epigenetic dysregulation in the acquisition of chemoresistance at relapse.
We hypothesized that there may be an existing drug whose effect on gene expression might mimic reversal of the relapse signature and may therefore functionally restore chemosensitivity in leukemic blasts. We searched the Connectivity map database 17, 18 to "query" our relapse signature, and identified the HDACi vorinostat as the top candidate agent which could potentially endow a chemosensitive gene expression profile. We validated this finding by demonstrating reversal of the relapse signature in primary B-lymphoblastic leukemia patient samples and cell lines treated with vorinostat that correlated with modulation of key epigenetic histone modifications. We further questioned whether a DNMTi could reverse relapse-specific promoter hypermethylation and re-express aberrantly silenced genes, and confirmed this in ALL cell lines treated with the DNMTi decitabine. Finally, we tested whether "epigenetic reprogramming" with each agent alone or the combination of HDACi and DNMTi may functionally restore chemosensitivity. By treating primary patient samples and cell lines with vorinostat and decitabine, we demonstrated enhanced chemosensitivity that correlated with modulation of aberrant relapse-specific signature. Our data suggests that incorporation of epigenetic agents into conventional treatment regimens may improve the outcome of relapsed childhood ALL.
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Materials and Methods

Cells
Primary patient samples were collected from patients treated at the New York University Medical Center and from the Children's Oncology Group (COG) cell bank. Samples were collected under the respective center's institutional review board-approved cell procurement protocols for children with ALL. Informed consent was obtained in accordance with the Helsinki protocol. Of the total 7 samples, 4 were from initial diagnosis and 3 were collected at the time of 
Connectivity Map
The Connectivity map (cmap) is a collection of genome-wide transcriptional expression data from cultured human cells treated with various bioactive small molecules. Using a nonparametric, rank-based pattern-matching strategy based on the Kolmogorov-Smirnov statistic, this analysis provides a ranked order of individual treatment instances based on their similarity to a given gene expression profile. The current version of the cmap data set (build02) (Table   S2 ). Wilcoxon paired signed-rank test was used to test the significance of change.
Western Blotting
Reh cells were treated with or without vorinostat (1 µM) and cell lysates were prepared using the histone extraction protocol (acid extraction) following the manufacturer's instructions (Abcam, Cambridge, MA). Lysates were probed with purified rabbit polyclonal anti-acetyl histone H3 at 1:5000 dilution (# 06-599, Millipore, Bellerica, MA) and the levels of acetyl-H3 was determined relative to a housekeeping gene, actin, at 1:2000 dilution (Abcam, Cambridge, MA). Signals were visualized using the Odyssey infrared imaging system (LI-COR, Lincoln, NE).
Chromatin Immunoprecipitation
Chromatin immunoprecipitation was carried out following the protocol provided by EZ-ChIP (Millipore) with few modifications. Briefly, Reh cells (1 x 10 6 ) were grown in RPMI with 10%
FBS with or without vorinostat (1 µM) for 24 hours. Proteins were cross-linked to DNA with 1%
formaldehyde added directly to culture medium for 10 min at 37°C, followed by cell lysis with SDS. The cell lysates were sonicated to shear DNA to the length of 200-1000 base pairs (bp).
Chromatin solutions were precipitated overnight at 4°C using 2 µg of anti-H3K9ac (# 334481, Qiagen, Valencia, CA), anti-H3K27me2 (#ab24684, Abcam), anti H3K4me2/me3 (#ab6000, Abcam) and antiH3K9me3 (# ab8898, Abcam). For the negative control, species specific IgG was used. For a positive control, anti-RNA polymerase II (# 05-623, Millipore) was used. DNA from protein-associated complexes and corresponding input samples were recovered using the QIAquick PCR purification kit (Qiagen) and assayed by real time PCR under standard
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Methylation Specific PCR
Genomic DNA was extracted from B-lineage leukemia (Reh and UOCB1) and B-lymphoma cell lines (Raji); and sodium bisulfite modification was performed using Epitect bisulfite kit (Qiagen) according to manufacturer's protocol. After this, methylation specific PCR (MSP) was performed as described previously. 19 Completely methylated and unmethylated control DNA (Epitect PCR control DNA set-Qiagen) was tested for each primer pair. PCR products were analyzed following electrophoresis on 2% agarose gels containing ethidium bromide. MSP primers are described in supplemental data (Table S2) .
Cell Viability Assays
CellTitre-Glo Luminescent Cell Viability assays (Promega, Madison, WI) were performed on primary patient samples and cell lines grown in appropriate survival conditions as described 
Results
Connectivity map analysis identifies vorinostat as top candidate agent which could reverse the relapse specific gene expression signature
Following the identification of the relapse specific drug resistant signature, we searched the current version of the cmap database to identify agents that could potentially reverse this signature and restore chemosensitivity. All treatment instances from the database were ranked according to their negative connectivity scores with a p-value <0.05. Remarkably, compounds which ranked amongst the top were the HDAC inhibitors vorinostat and trichostatin A. The average connectivity score of the 12 treatment instances of vorinostat in various cancer cell lines in the cmap database was -0.659 (p value=0) while the 182 instances of trichostatin A had a connectivity score of -0.452 (p value=0) ( Figure S1 ). This analysis indicated that the genetic make-up of relapsed ALL might be epigenetically driven and hence its reversal by histone deacetylase inhibitors could potentially restore chemosensitivity.
Gene expression microarrays and RT-PCR validates the Connectivity map results
To validate and confirm the Connectivity map findings, primary patient samples (n=3) and leukemia cell lines (Reh, RS4:11, MV4:11) were treated with 1 µM of vorinostat and incubated for 24 hours. RNA was extracted and gene expression profiling was performed on Affymetrix U133Plus2 array. The expression of 38.7% (mean) (95% confidence interval across the 6 samples being 30.51-46.18%) of genes differentially expressed at relapse was reversed following vorinostat treatment using the fold change of 0.8 and 1.2 for down and up regulated genes respectively and a p value <0.05 ( Figure 1) . Details of individual genes and corresponding reversal upon vorinostat treatment have been outlined in supplemental data (Table S1 ). To determine whether the relapse signature is enriched for genes whose expression is epigenetically regulated as compared to the whole genome, we examined expression changes in genes using a more stringent fold change of 2. The expression of 17.8% (mean) (95% confidence interval across the 6 samples being 12.7-22.8%) of the relapse specific genes were reversed after vorinostat treatment, compared with only 12.8 % (mean) (95% confidence interval across 6 samples being 8.8-16.7%) genes were affected in the whole genome analysis (p = 0.025 by chi square test). This result was also validated using a random sampling method where 10,000 1 0 random combinations showed that in only 185 instances could such a finding be attributable to chance alone (p = 0.019). These two independent methods show a specific effect of vorinostat on the genes included in the relapse specific signature. Microarray data were then validated by RT-PCR in a selected set of candidate chemoresistance genes from our previous publication, 16 which showed significant downregulation of the expression of BIRC5, FOXM1, TYMS and FANCD2
(genes upregulated at relapse) (Figure 2A ), while an increase in the expression of NR3C1, HRK and SMEK2 (genes downregulated at relapse) ( Figure 2B ).
Association of histone marks correlates with vorinostat exposure as histone deacetylase inhibitor
The and not found to be hypermethylated in our relapse cohort, although it has been shown to be hypermethylated in other cancer types. 23 Again, no change in expression of NR3C1 was observed following decitabine treatment in either cell line.
MSP demonstrates the effect of decitabine on promoter hypermethylation and validates
RT-PCR results
To demonstrate the direct effect of decitabine on promoter hypermethylation, MSP was performed with cell lines before and after treatment with decitabine. The PTPRO and HOXA9 genes were completely methylated in Reh and UOCB1 cell lines prior to treatment and an enrichment of the unmethylated amplicon was observed following treatment with decitabine (1 µM). The GATA4 promoter was preferentially methylated in both cell lines, though some unmethylation was also observed at baseline which was significantly enriched after treatment 
Pretreatment with vorinostat and/or decitabine induces chemosensitivity in primary patient samples and leukemia cell lines
Finally, to examine whether epigenetic priming translates to increased chemotherapy-induced cytotoxicity of leukemic blasts, we assessed cytotoxicity with a panel of chemotherapeutic agents commonly used in ALL therapy. Primary patient samples (n=7) and Reh and RS4:11 cell lines were treated sequentially with increasing concentrations of vorinostat and/or decitabine at hour 0, followed by application of conventional chemotherapeutic agents (prednisolone, doxorubicin, cytarabine and etoposide) at varying concentrations at hour 24 or 48. Cytotoxicity assays were performed at hours 48 or 72. Vorinostat alone induced 40-60% of cytotoxic effect at the maximal concentration of 2.5 µM. An additive or synergistic effect was observed when cells were pretreated with vorinostat followed by chemotherapy in Reh and RS4:11 cell lines (CI=0.5-1.05) ( Figure S2A and S2B) . Similarly, decitabine alone induced 25-40% of cytotoxic effect at its maximal concentration used and addition of chemotherapy following decitabine pretreatment significantly increased the amount of cytotoxicity (CI 0.34-0.9) (Figure S2C and S2D) . The two epigenetic drugs by themselves showed mostly additive effect to moderate synergism (CI=0.57-1.1), while pretreatment with both vorinostat and decitabine followed by prednisolone had the most robust cytotoxicity compared to any other combination, showing strong synergism (CI=0.17-0.5) (Figure 5A-D) . As predicted from the Connectivity Map results, we did observe For personal use only. on August 16, 2017. by guest www.bloodjournal.org From increased cytotoxicity in the relapse samples (n=3) when vorinostat alone was followed by prednisolone (CI=0.36-0.6) as compared to the diagnosis samples (n=4) (CI=0.43-1.0) ( Figure   5C and 5D), though the comparison was limited due to small sample size. This data suggests that although both the diagnosis and relapse blasts can be sensitized to chemotherapy, the effect of vorinostat was more pronounced in the relapsed blast population. We did not see this effect with decitabine where the impact was equivalent in both initial diagnosis and relapse. For
Discussion
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Genome-wide methylation assays have identified many cancer-related genes as substrates of DNMTs leading to epigenetic silencing. In this study, we were able to show re-expression of many genes which were hypermethylated at relapse by both RT-PCR and concordant promoter hypomethylation by MSP. Of these, CDKN2A, PTPRO and CSMD1 have previously been identified as tumor suppressors in many cancers 40, 41 and reactivation with demethylating agents is a logical approach. Furthermore, WT1 and APC are inhibitors of the β -catenin/TCF/LEF complex and were differentially down-regulated and hypermethylated in the relapse cohort. In the current study, a significant up-regulation of WT1 after decitabine exposure is demonstrated.
However, there was no significant baseline hypermethylation of APC in the Reh and UOCB1
cell lines, and hence failed to demonstrate decitabine effect. Finally and most importantly, not only was aberrant gene expression reprogrammed by these two agents, but combination treatment with vorinostat and decitabine synergized with standard chemotherapy agents to result in enhanced chemosensitivity. Larger sample size would be needed to further compare the effect of these agents on the diagnosis versus relapsed blasts.
The combination of vorinostat and decitabine has previously been tested in human leukemia
showing evidence of cell growth inhibition and gene silencing. 42 Recently, Kalac et al has also
shown highly synergistic combination of HDACi (panobinostat) and DNMTi (decitabine) and association with unique gene expression and epigenetic profiles in large B cell lymphoma.
43
Although newer HDAC and DNMT inhibitors are under active investigation, we focused on vorinostat and decitabine not only because they are FDA approved, but also because Phase 1 trials using these agents have shown their safety in the pediatric population. 44, 45 Reversal of gene expression and methylation signature in our study was seen with 1 µ M concentration of vorinostat and decitabine respectively, a plasma concentration which was shown to be clinically achievable and tolerable in these phase 1 clinical trials. Ravandi et al reported this combination to be well tolerated in a phase 1 study in hematologic malignancies in adults. 46 Additional support for the feasibility of this combination has recently been published in adults with solid tumors and Non-Hodgkin's lymphoma. 47 Moreover, it has been shown in previous reports that apoptosis induced by these epigenetic agents are specific to the malignant cell population, and have comparatively little or no activity against their normal counterparts (non malignant cells), 1 6 50 suggesting that incorporating these agents episodically in the standard reinduction chemotherapy backbone for the treatment of relapsed ALL is feasible.
Overall, our data reveals an attractive approach to reverse the drug resistance gene signature to restore chemosensitivity in relapse ALL. Our study validates this approach in pre-clinical assays.
Data described in this manuscript has led to a multi-institutional Phase 1 clinical trial evaluating the feasibility and safety of using the combination of these epigenetic agents that is set to accrue patients through the Therapeutic Advances in Childhood Leukemia and Lymphoma Consortium (http://Clinicaltrials.gov:NCT01483690). Gene expression and methylation arrays and subsequent validation studies will be undertaken as part of correlative biology assays for this clinical protocol. Our data provides a strong rationale for undertaking such a trial to improve the cure-rates in relapsed childhood ALL, which otherwise has a dismal prognosis.
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